Nootropic Peptide — 10mg/vial
$90.16 AUD
Third-party HPLC tested. COA published for every batch.
💧 Need BAC water? 30mL bacteriostatic water available — $21.90 ($13 less than AU competitors). Add to your order.
Selank is a synthetic heptapeptide analogue of the immunomodulatory peptide tuftsin, developed at the Russian Academy of Sciences' Institute of Molecular Genetics (IMG) in Moscow. First synthesised in the 1990s, Selank was registered as an approved pharmaceutical in Russia in 2009 for the treatment of anxiety disorders, neurasthenia, and cognitive impairment.
Unlike benzodiazepines, preclinical research demonstrates anxiolytic effects without sedation, muscle relaxation, cognitive impairment, or withdrawal syndrome — representing a fundamentally different class of anxiolytic compound. Its unique therapeutic index has made it a compound of significant interest across neuroscience, psychiatry, and immunology research.
"FOR RESEARCH USE ONLY. This information is provided for scientific and educational purposes only. It does not constitute medical advice or a recommendation for human use."
| Compound | Selank |
| Form | Lyophilized powder |
| Dosage | 10mg/vial |
| Purity | 99%+ (HPLC verified) |
| Testing | Third-party HPLC + MS |
| Storage | 2-8°C (refrigerated) |
| Origin | GMP facility |
Selank's primary mechanism involves potentiation of the GABAergic system — specifically enhancement of GABA-A receptor function — producing anxiolytic effects without direct benzodiazepine receptor binding. This explains the notable absence of sedation, cognitive impairment, and withdrawal syndrome that typically accompany classical benzodiazepine ligands.
Research also demonstrates modulation of dopaminergic and serotonergic neurotransmission, upregulation of BDNF and enkephalin expression, and inhibition of enkephalin-degrading enzymes (prolonging endogenous opioid tone). Its tuftsin-derived sequence contributes immunomodulatory and reported antiviral activity. The peptide reaches the central nervous system via intranasal olfactory transport, bypassing the blood-brain barrier — a distinct delivery advantage for CNS research.
Every batch independently tested via HPLC and Mass Spectrometry. COAs published on site.
Based in Australia with express shipping nationwide. Discreet, temperature-controlled packaging.
Every batch independently tested via HPLC and Mass Spectrometry. COAs published on site with full batch details.
Selank potentiates GABA-A receptor function differently than benzodiazepines. Where benzodiazepines bind directly to the benzodiazepine site of GABA-A receptors (producing sedation, tolerance, and withdrawal), Selank enhances GABAergic transmission through an alternative mechanism. Animal models show anxiolytic effects without sedation, muscle relaxation, cognitive impairment, or withdrawal syndrome.
Selank is commonly administered intranasally in preclinical research (the peptide bypasses the blood-brain barrier via olfactory transport). Subcutaneous and intramuscular routes are also documented in the literature. Standard research protocols use 200–800 µg/kg/day. Always follow your institution's ethical guidelines.
Selank demonstrates good stability as a lyophilized powder when stored at 2–8°C. Once reconstituted with bacteriostatic water, it should be used within 7–14 days. The peptide's tuftsin-derived structure contributes to its favourable stability compared to some other short peptides.
Selank is legal to purchase for legitimate research purposes in Australia. It is not a scheduled substance when intended for research use only. All sales are strictly for laboratory research purposes — not for human or veterinary consumption.
Enter your email and we'll alert you the moment it's back in stock.